aibioIdorsia takes up to CHF 250 million senior secured term loan
Tickers IDIA
The first CHF 150 million tranche will refinance the existing New Money Facility, of which CHF 105 million has been drawn.
Key facts
- Company
- Idorsia Ltd. (SIX: IDIA)
- News type
- Debt Financing
- Primary source
- Idorsia Ltd (2026-06-09)
Idorsia Ltd said it entered into a senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP. The release describes Idorsia as a commercial-stage biopharmaceutical company, listed on the SIX Swiss Exchange as SIX: IDIA.
The first tranche of CHF 150 million will be provided at closing. The proceeds will initially be used to fully refinance the existing New Money Facility. The company said CHF 105 million has been drawn under that facility, which is scheduled to mature in May 2027.
The release says the refinancing eliminates near-term debt maturities and materially enhances Idorsia's liquidity profile.
The lender is the group of investment funds managed by Pharmakon Advisors, LP. The release names no placement agent or advisor for the loan.